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Summary
AIMS OF THE STUDY: In recent years, the Swiss Federal
Office of Public Health (FOPH) granted exceptional licens-
es for the medical use of cannabinoids, typically for 6
months with possible extensions. A systematic review of
cannabinoids for medical use commissioned by the FOPH
supports the use of cannabinoids for the treatment of
chronic pain and spasticity. However, little is known about
the patients treated with cannabinoids. We aimed to study
medical uses of cannabinoids as part of the FOPH’s pro-
gramme of exceptional licenses.
METHODS: We examined all requests for medical use of
cannabinoids sent to FOPH in 2013 and 2014. A standard-
ised data sheet was developed to extract data from the
files of approved requests. We extracted the duration of
the licence, the year it was granted, and the payer of the
therapy. At the level of the patient we collected the date of
birth, sex, region of residence, diagnosis and the indica-
tion. Ethical approval was granted by the Ethics Commit-
tee of the Canton of Bern.
RESULTS: We analysed 1193 patients licenced for
cannabinoid treatment in 2013 or 2014. During 2013, 542
patients were treated under the exceptional licencing pro-
gramme (332 requesting physicians) compared with 825
in 2014 (446 physicians). Over half of patients (685; 57%)
were women. The mean age was 57 years (standard devi-
ation 15.0), chronic pain (49%) and spasticity (40%) were
the most common symptoms, and co-medication was re-
ported for 39% of patients. Seventy-eight different diag-
noses were recorded, including multiple sclerosis (257 pa-
tients, 22%), soft tissue disorders (119, 10%), dorsalgia
(97, 8.1%), spinal muscular atrophy (65, 5.5%) and para-
plegia/tetraplegia (62, 5.2%). Licence extensions were
granted to 143 patients (26.4%) in 2013 and 324 patients
(39.3%) in 2014. There were substantial regional varia-
tions of the rates of patients treated with cannabinoids. On
average, eight patients per 100 000 residents received an
exceptional licence. Most patients (1083, 91%) paid out of
pocket.
CONCLUSIONS: Exceptional licences for medical use of
cannabinoids have increased substantially in Switzerland,
with the programme including patients with a wide range
of conditions.
Key words: Evaluation, medical cannabis, official
records, chronic diseases, clinical epidemiology, pain ther-
apeutics, musculoskeletal system, nervous system
Introduction
Cannabinoids have been used to treat chronic pain, spas-
ticity, nausea, and other symptoms since the middle of
the 19th century [1, 2]. The chemical characterisation of
the psychoactive substance delta-9-tetrahydrocannabinol
(THC) in 1964 laid the foundation for the scientific study
of cannabinoids [3]. Subsequently it became clear that the
effects of THC are due to the activation of endogenous
cannabinoid receptors within a newly discovered endo-
cannabinoid system (ECS) [4]. More recently, the ECS has
been associated with an increasing number of functional
pathways, both in the central and peripheral nervous sys-
tems and in peripheral organs, and the ECS has emerged as
a target of pharmacotherapy [5–10].
Endocannabinoids naturally produced in the body, for ex-
ample in stress situations, modulate the ECS system and
affect inflammation and the sensation of pain [7, 11]. In
the 1970s, the effect of THC on pain was compared to that
of codeine [12], and more recent studies showed that THC
is equivalent to conventional analgesics [13]. Studies in
cancer patients found that cannabinoids improved appetite,
reduced emesis and nausea, and improved quality of life
[14–16]. Cannabinoids have also been shown to be effec-
tive in neuropathic pain and diseases of the peripheral or
central nervous system [17, 18].
The International Drug Control Conventions classify THC
as an illegal, schedule I drug (together with opioids, opium
derivatives, and hallucinogenic or psychedelic substances)
and prohibit all use “except for scientific and very limited
medical purposes by duly authorized persons” [19]. In
Switzerland, the 2011 revision of the Federal Act on Nar-
cotics and Psychotropic Substances (Narcotics Act) made
it possible for the Federal Office of Public Health (FOPH)
to issue exceptional licenses for the restricted medical use
of some prohibited substances, including THC.
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A systematic review of cannabinoids for medical use com-
missioned by the FOPH concluded that “there was mod-
erate-quality evidence to support the use of cannabinoids
for the treatment of chronic pain and spasticity” [20]. To
look more closely at this and other uses of medical uses of
cannabinoids, we studied all of the exceptional licences for
medical use of cannabis issued by the Swiss FOPH in 2013
and 2014.
Materials and methods
Data source and data extraction
Physicians practising in Switzerland are required to submit
a formal request to the FOPH for each patient they wish
to treat with cannabinoids, either with commercially avail-
able synthetic THC (dronabinol solution with 2.5% THC)
or a tincture of Cannabis sativa prepared by a pharmacist
containing 5% THC [21]. The physician’s request must
document the diagnosis of a severe or potentially life-
threatening condition, address the benefit expected from
THC treatment, and include the informed consent of the
patient.
We examined all requests for medical use of cannabinoids
sent to the FOPH in 2013 and 2014. We developed, tested
and revised a standardised data extraction sheet to extract
data from the files of approved requests. We created unique
identification (ID) numbers and extracted data on the type
of exceptional licence granted, the patient, and the treating
physician. We extracted the duration of the licence, the
year it was granted, and the payer for the therapy (out of
pocket or insurance). At the level of the patient we collect-
ed the date of birth, sex, regional code, diagnosis and in-
dication for THC use, and at the level of the physician the
regional code of the surgery and the treating physician’s
specialisation. We double-entered the data into a dedicated
database in Epidata [22] and resolved discrepant data en-
tries.
Definitions
We allocated patient and physician to the seven Swiss re-
gions defined by the Nomenclature of Territorial Units for
Statistics (NUTS, level II) [23]. These regions are shown
in supplementary figure S1 (appendix). We used the In-
ternational Statistical Classification of Diseases (ICD-10)
[24] to categorise diagnoses into ten groups (ICD-10 codes
in parentheses):
1. Infectious and parasitic diseases (A00–B99)
2. Cancer (C00–C97)
3. Mental and behavioural disorders (F00–F99)
4. Diseases of the nervous system (G00–G99)
5. Diseases of the circulatory system (I00–I99)
6. Diseases of the respiratory system (J00–J99)
7. Diseases of the digestive system (K00–K93)
8. Diseases of the musculoskeletal system (M00–M99)
9. Injury, poisoning, and other conditions with external
causes (S00–T98)
10. Other diagnoses.
We used the Swiss Medical Association classification sys-
tem for the specialisation and further certification of physi-
cians [25].
Statistical methods
We used descriptive statistics (numbers and percentages)
to present results of the requests and the characteristics of
patients granted exceptional licences for therapeutic use of
cannabinoids. Patient characteristics were taken from the
first application for the same patient received in the years
2013 and 2014. We examined patient characteristics by the
main symptoms pain and spasticity, and present detailed
information on the underlying diagnoses reported for pa-
tients granted exceptional licenses for therapeutic use of
cannabinoids. Finally, we calculated the rate of patients
granted access per 100 000 residents by NUTS II region
using the population statistics available from the European
Union (Eurostat) [26]. We used Stata software version 14.1
(Stata Corporation, College Station, Texas, USA) for all
analyses. Ethical approval was granted by the Ethics Com-
mittee of the Canton of Bern (KEK-Nr. 296/15).
Results
The FOPH received 1656 requests for initial exceptional
licences and licence extensions to prescribe THC during
2013 and 2014. Eight requests from eight patients were re-
jected and 1648 licences and extensions for 1208 patients
were approved. Requests were rejected for incompatibility
with the law (for example, requests for “substitution ther-
apy”) or for administrative reasons. Fifteen patients were
excluded because of missing data in key variables. Thus,
during these two years, 1193 unique patients received ex-
ceptional licences for treatment with cannabinoids and
were included in the analyses (fig. 1). During 2013, 542
patients were treated under the exceptional licencing pro-
gramme, and in 2014 the number rose to 825, including
some who continued treatment begun in 2013 or earlier.
The approved licenses were requested by 332 physicians
in 2013 and 446 physicians in 2014. More than half (55%)
of the prescribing physicians were internal medicine spe-
cialists and 14% were neurologists. Other specialisations
included 17 (2.7%) physicians who specialised in interven-
tional pain therapy, 9 (1.4%) certified in acupuncture, and
7 (1.1%) with certificates in homeopathy.
Figure 1: Flowchart of formal requests for medical use of cannabi-
noids 2013–2014 to the Federal Office of Public Health and excep-
tional licences granted and included in the study. The figure shows
the numbers of unique patients and (in brackets) the numbers of
exceptional licences.
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Most patients (1083, 91%) paid for treatment out of pocket
(typically amounting to US$ 400–500 per month). Only 95
patients (7.8%) were reimbursed by Switzerland's compul-
sory basic health insurance, with a further 15 (1.3%) reim-
bursed by disability or accident insurance.
Patient characteristics
The majority of the 1193 patients were women (685 pa-
tients, 57%), the mean age was 57 years (standard devia-
tion 15 years), and most patients had neurological (580 pa-
tients, 49%) or musculoskeletal (300, 25%) conditions, or
one of 19 different cancer diagnoses (121 patients, 10%).
The most common complaints and indications for THC
therapy were chronic pain (49%) and spasticity (40%). The
characteristics of patients are summarised in table 1.
Diseases of the nervous system and spasticity were more
common in men, and musculoskeletal conditions and
chronic pain more common in women. The majority of pa-
tients (734, 62%) took no comedication. Among those who
took at least one, the most frequently used medication was
an analgesic (237 of 459 patients, 52%).
Compared with patients with spasticity, those with pain
(including neuropathic pain) were older (mean age 60 vs
53 years), more likely to suffer from musculoskeletal con-
ditions or cancer, and less likely to be reimbursed by health
insurance (supplementary table S1).
Diagnoses
Multiple sclerosis was the single most common diagnosis
(257 patients, 22%). A list of the most common diagnoses
within the ten diagnostic groups is provided in table 2. The
diagnosis was unclear in 75 patients (6.3%). A complete
list of all recorded diagnoses in patients granted exception-
al licences is given in supplementary table S2.
Table 1: Characteristics of patients granted exceptional licences for therapeutic use of cannabinoids by gender.
Variable Female (n = 685) Male (n = 508) Total (n = 1193)
Age (years)
10–19 6 (0.9) 8 (1.6) 14 (1.2)
20–39 64 (9.3) 60 (11.8) 124 (10.4)
40–64 380 (54.9) 302 (59.5) 682 (57.2)
65–79 187 (27.3) 111 (21.9) 298 (25.0)
80–99 48 (7.1) 27 (5.3) 75 (6.3)
Mean (standard deviation), years 58 (14.8) 56 (15.1) 57 (15.0)
Diagnosis group (ICD-10 codes)
Diseases of the nervous system (G00–G99) 312 (45.6) 268 (52.8) 580 (48.6)
Diseases of the musculoskeletal system (M00–M99) 209 (30.5) 91 (17.9) 300 (25.2)
Cancer (C00–C97) 74 (10.8) 47 (9.3) 121 (10.1)
Injury, poisoning, and other conditions with external causes (S00–T98) 19 (2.8) 29 (5.7) 48 (4.0)
Diseases of the circulatory system (I00–I99) 9 (1.3) 14 (2.8) 23 (1.9)
Infectious and parasitic diseases (A00–B99) 14 (2.0) 8 (1.6) 22 (1.8)
Mental and behavioural disorders (F00–F99) 6 (0.9) 11 (2.2) 17 (1.4)
Diseases of the digestive system (K00–K93) 2 (0.3) 4 (0.8) 6 (0.5)
Diseases of the respiratory system (J00–J99) 0 (0.0) 1 (0.2) 1 (0.1)
Unclear 40 (5.8) 35 (6.9) 75 (6.3)
Main symptom
Chronic pain 365 (53.3) 224 (44.1) 589 (49.4)
Spasticity 257 (37.5) 219 (43.1) 476 (39.9)
Neuropathic pain 19 (2.8) 24 (4.7) 43 (3.6)
Lack of appetite 21 (3.1) 21 (4.1) 42 (3.5)
Nausea 15 (2.2) 11 (2.2) 26 (2.2)
Tremor 8 (1.2) 9 (1.8) 17 (1.4)
Comedication*
None 411 (60.0) 323 (63.6) 734 (61.5)
At least one drug 274 (40.0) 185 (36.4) 459 (38.5)
Analgesics 154 (56.2) 83 (44.9) 237 (51.6)
Muscle relaxant 89 (32.4) 75 (40.5) 164 (35.7)
Anticonvulsant 72 (26.3) 48 (26.0) 120 (26.1)
Immunosuppressive 16 (5.8) 10 (5.4) 26 (5.7)
Cytotoxic agents 13 (4.7) 7 (3.8) 20 (4.4)
Antidepressants 20 (7.3) 12 (6.5) 32 (7.0)
Antiemetic drugs 6 (2.2) 3 (1.6) 9 (2.0)
Parkinson medication 1 (0.4) 4 (2.2) 5 (1.1)
Others 6 (2.2) 10 (5.4) 16 (3.5)
Reimbursement
None (out of pocket) 627 (91.5) 456 (90.2) 1083 (90.8)
Health insurance 55 (8.0) 40 (7.9) 95 (7.8)
Disability / accident insurance 3 (0.4) 12 (2.4) 15 (1.3)
Numbers (%) are shown * It is possible that patients received more than one treatment
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Extensions to exceptional licences
In most cases, licences were initially granted for 6 months.
Physicians requested extensions when the effect of the
treatment had, in their assessment, been satisfactory. The
number of extensions increased from 143 of the 542 pa-
tients in 2013 (26.4%) to 324 of 825 patients in 2014
(39.3%). Table 2 lists the numbers of extensions per diag-
nosis. Multiple sclerosis patients not only were granted the
Table 2: List of most common diagnoses in patients granted exceptional licenses for therapeutic use of cannabinoids and extensions.
Diagnosis (ICD-10 codes) Patients (n = 1193) Extensions (n = 209)
Diseases of the nervous system (G00–G99) 580 (48.6) 144 (68.9)
Multiple sclerosis 257 (21.5) 76 (36.4)
Spinal muscular atrophy and related syndromes 65 (5.5) 17 (8.1)
Paraplegia and tetraplegia 62 (5.2) 13 (6.2)
Hereditary and idiopathic neuropathy 30 (2.5) 3 (1.4)
Parkinson disease 17 (1.4) 2 (1.0)
Nerve root and plexus disorders 15 (1.3) 5 (2.4)
Migraine 13 (1.0) 0
Cerebral palsy 11 (0.9) 4 (1.9)
Other disorder of central nervous systems 10 (0.8) 2 (1.0)
Hemiplegia 10 (0.8) 4 (1.9)
Other extrapyramidal and movement disorders 9 (0.8) 1 (0.5)
Epilepsy 8 (0.7) 1 (0.5)
Other polyneuropathies 8 (0.7) 2 (1.0)
Other paralytic syndromes 8 (0.7) 2 (1.0)
Huntington disease 6 (0.5) 1 (0.5)
Other headache syndromes 6 (0.5) 3 (1.4)
Disorders of trigeminal nerve 6 (0.5) 0
Other diseases of spinal cord 6 (0.5) 0
Other diseases of the nervous system 33 (2.8) 8 (3.8)
Diseases of the musculoskeletal system (M00–M99) 300 (25.2) 36 (17.2)
Soft tissue disorders, not elsewhere classified 119 (10.0) 20 (9.6)
Dorsalgia 97 (8.1) 8 (3.8)
Polyarthrosis 19 (1.6) 2 (1.0)
Other systematic involvement of connective tissue 13 (1.1) 2 (1.0)
Other arthritis 12 (1.0) 1 (0.5)
Other rheumatoid arthritis 11 (0.9) 1 (0.5)
Other joint disorders, not elsewhere classified 10 (0.8) 0
Seropositive rheumatoid arthritis 8 (0.7) 0
Other diseases of the musculoskeletal system 11 (0.9) 2 (1.0)
Cancer (C00–C97) 121 (10.1) 7 (3.4)
Breast 29 (2.4) 2 (1.0)
Lung 18 (1.5) 0
Colon 12 (1.0) 0
Pharynx and oesophagus 8 (0.7) 0
Pancreas 8 (0.7) 1 (0.5)
Stomach 6 (0.5) 1 (0.5)
Prostate 6 (0.5) 1 (0.5)
Hodgkin lymphoma 5 (0.4) 0
Other cancers 29 (2.4) 2 (1.0)
Injury, poisoning, and other conditions with external causes (S00–T98) 48 (4.0) 8 (3.8)
Complications of surgical and medical care, not elsewhere classified 48 (4.0) 8 (3.8)
Diseases of the circulatory system (I00–I99) 23 (1.9) 1 (0.5)
Cerebral infarction 9 (0.8) 0
Other diseases of the circulatory system 14 (1.2) 1 (0.5)
Infectious and parasitic diseases (A00–B99) 22 (1.8) 0
Zoster (Herpes zoster) 9 (0.8) 0
HIV diseases resulting in infectious and parasitic disease 7 (0.6) 0
Other bacterial diseases, not elsewhere described 6 (0.5) 0
Mental and behavioural disorders (F00–F99) 17 (1.4) 2 (1.0)
Tic disorder 11 (0.9) 1 (0.5)
Somatoform disorders 5 (0.4) 1 (0.5)
Recurrent depressive disorder 1 (0.1) 0
Diseases of the digestive system (K00–K93) 6 (0.5) 0
Diseases of the respiratory system (J00–J99) 1 (0.1) 0
Unclear 75 (6.3) 11 (5.3)
Numbers (%) are shown
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most extensions, but also received the highest proportion
of extensions per diagnosed patient: 76 extensions for 257
patients (29.6%). As shown in table 3, 144 of 209 total ex-
tensions (69%) were granted for diseases of the nervous
system, and 36 extensions (17%) were granted for diseases
of the musculoskeletal system. In terms of symptoms, 75
extensions were granted to the 514 patients (14.6%) ini-
tially reporting chronic pain, while for patients reporting
spasticity, 123 of 353 patients (34.8%) were granted exten-
sions. Unfortunately, for the patients who did not apply for
extensions and stopped treatment, no further information is
available in the FOPH records regarding whether cannabi-
noid treatment cured their disease or alleviated their symp-
toms, and physicians’ reports on treatment effectiveness
were not required.
One patient died during the treatment (death was not
caused by cannabinoids).
Regional variation
The rates of patients treated with cannabinoids per 100 000
residents increased from 2013 to 2014 in all regions, but
varied substantially across the seven regions. In 2014 the
rate was 3.6 in the region along the Lake of Geneva, 5.0
in Central Switzerland, and between 7.1 and 8.2 in all
other regions except for the Ticino, where the rate was
much higher, 36.9 per 100 000 residents (supplementary
fig. S2). This could be due to a small number of frequent
prescribers in this region.
Discussion
The medical use of cannabinoids through exceptional li-
censes increased substantially in Switzerland during the
2-year study period and involved patients with 78 different
conditions. Prescriptions for neurological and muscu-
loskeletal conditions predominated, followed by cancer.
More women sought treatment with cannabinoids than
men. Regionally, the cannabinoid treatment rate varied but
was considerably higher in Italian-speaking Ticino than
the rest of Switzerland. Additional drugs taken by patients
were mostly analgesics, muscle relaxants and anticonvul-
Table 3: Main symptoms of patients granted exceptional licences for
therapeutic use of cannabinoids, separated by initial and extension li-
cence.
Main symptom Initial (n =
984)
Extension
(n = 209)
Total (n =
1193)
Chronic pain 514 (52.2) 75 (35.9) 589 (49.4)
Spasticity 353 (35.9) 123 (58.9) 476 (39.9)
Neuropathic pain 38 (3.9) 5 (2.4) 43 (3.6)
Lack of appetite 41 (4.2) 1 (0.5) 42 (3.5)
Nausea 23 (2.3) 3 (1.4) 26 (2.2)
Tremor 15 (1.5) 2 (1.0) 17 (1.4)
Numbers (%) are shown
sants. As for physicians, more than half of those prescrib-
ing cannabinoids specialised in internal medicine, and the
next largest specialty was neurology (though internists out-
number neurologists by 4:1). Regarding payment for treat-
ment, only one in 10 patients was reimbursed by health in-
surance.
Medical use of cannabinoids is growing in other countries
as well (e.g., Germany, The Netherlands, United States of
America, Canada, France, Spain, Israel) [27]. Table 4 com-
pares published surveys of medical uses of cannabinoids in
different countries with the current study [28–32]. Age dis-
tributions of medical cannabis users differ internationally,
but overall Swiss patients are generally older than users of
cannabis for medical purposes in the US, Canada and Aus-
tralia [30, 31]. In the international survey conducted in 31
countries by the International Association for Cannabinoid
Medicines (IACM), the mean age of cannabinoid users
was 40.7 years, with 44.9% in the 41–60 age group [28].
Medical cannabis use varies by gender as well, but unlike
in Switzerland, male users predominate in the US, Canada,
and Australia [30, 31], and in the IACM study, 64% of pa-
tients were men [28].
Chronic pain figured in almost half of Swiss exceptional
licences in 2013 and 2014, and worldwide the main symp-
tom treated by medical cannabis is also pain. In addition to
chronic pain, the IACM study reported treatment for anx-
iety (18.3%), loss of appetite (10.7%), depression (5.2%)
and insomnia (5.1%) [28]. Like pain, spasticity also is a
major symptom treated with cannabinoids in Switzerland,
but it does not appear to be an important symptom in stud-
ies elsewhere. Of note, spasticity and chronic pain were the
two indications best supported by the systematic review of
the literature commissioned by the FOPH [20].
Medical cannabinoids may help lower the intake of opioid
medication, as well as lower opioid overdose mortality,
where the medical use of cannabis is legal [33]. A recent
study found a drop in prescriptions of pharmaceuticals in
several disease categories in US states that allow med-
ical cannabinoids [34]. The numbers on concomitant drug
intake in our study are low, which makes it difficult to
draw conclusions. Further study is required to understand
whether the use of cannabinoids leads to reductions in use
of other medications.
Even as the prescription of cannabinoids is growing, the
situation of physicians in North America is not always
straightforward. Physicians in Canada reported they were
not comfortable prescribing cannabinoids [35], and a study
in the US concluded that ophthalmologists need more ed-
ucation about the medical use of cannabinoids to better re-
spond to patient (mis)perceptions of the value of cannabis
in glaucoma therapy [36].
The North American context differs from the Swiss, al-
though in Switzerland, too, treatment with cannabinoids
Table 4: Comparison of international studies that examined medical use of cannabis.
Author (year) Country Patients (n) Main symptom Main diagnosis
Hazekamp et al. (2013) [28] 31 countries* 953 Back pain Sleep disorders
Ryan-Ibarra et al (2012) [29] USA 350 Chronic pain Arthritis
Swift et al. (2005) [30] Australia 128 Chronic pain Depression
Walsh et al. (2013) [31] Canada 628 Chronic pain Arthritis
Ware et al. (2005) [32] UK 947 Chronic pain Multiple sclerosis
Kilcher et al (present study) Switzerland 1193 Chronic pain Multiple sclerosis
* Most of the participants were from the USA
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still needs clarification. In 2013, for example, Swissmedic
approved Sativex®, which contains 27 mg THC and 25
mg cannabidiol per ml [37], for the treatment of medium
and heavy spasticity caused by multiple sclerosis. The use
of Sativex® for other indications (off-label use), however,
needs an exceptional license from the FOPH. At the same
time, 257 patients received exceptional licenses for
cannabinoid treatment of multiple sclerosis in 2013 to
2014, and many of them were granted extensions. Similar-
ly, 353 patients were granted licences for treatment of spas-
ticity for which 123 extensions, 58.9% of all extensions,
were approved. Since exceptional licenses ought not to be
issued to supplant another effective treatment, this rais-
es questions about the perceived effectiveness of Sativex®
among both patients and physicians.
This study of patient data in the FOPH cannabinoid licenc-
ing programme, the first of its kind in Switzerland, was
limited at the outset by the fact that the data do not include
information such as socioeconomic status, smoking, objec-
tive treatment outcomes or reasons to stop a treatment. In-
formation in the licences on concomitant drugs, diagno-
sis, and patient history was sometimes poorly reported as
well. The fact that some patients may treat themselves with
cannabis obtained on the black market is another issue that
may have influenced and distorted our results.
These limitations highlight the need for new research on
medical cannabis. A drug with long history of use, whether
legal or otherwise, can accrue claims of efficacy that in
time imbue it with promise that may border on that of a
wonder drug. As exceptional licencing of medical cannabi-
noids continues to expand in Switzerland, and the recre-
ational and medical use is legalised in an increasing num-
ber of states and countries, clear guidelines for safe and
effective use must urgently be developed, based on basic
research and clinical trials. It is indeed “high time for evi-
dence-based policies” [38].
Acknowledgements
We thank Nadine Tremp for help with data entry.
Disclosure statement
GK is an employee of the Swiss Federal Office of Public Health. The
content of this publication does not reflect in any way the views or
policies of the Federal Office of Public Health. ME, MZ, CR and LF
have no conflicts of interests to declare.
References
1 Fankhauser M. Haschisch als Medikament:[zur Bedeutung von
Cannabis sativa in der westlichen Medizin]. SGGP; 2002.
2 Le Foll B, Tyndale RF. Cannabinoids: Friend or foe? Clin Pharmacol
Ther. 2015;(6):528–31. http://dx.doi.org/10.1002/cpt.119. PubMed.
3 Mechoulam R, Gaoni Y. A Total Synthesis of DL-Delta-1-Tetrahydro-
cannabinol, The Active Constituent of Hashish. J Am Chem Soc.
1965;(14):3273–5. http://dx.doi.org/10.1021/ja01092a065. PubMed.
4 Grotenhermen F. Cannabis und Cannabinoide. Pharmakologie,
Toxikologie und Ther Potential 2nd Ed Göttingen Hans Huber. 2004
5 Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmaco-
logical considerations, relevant to future drug discovery and develop-
ment. Expert Opin Investig Drugs. 2000;(7):1553–71. http://dx.doi.org/
10.1517/13543784.9.7.1553. PubMed.
6 Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale
for clinical use. Forsch Komplementarmed. 1999;(Suppl 3):12–5.
http://dx.doi.org/10.1159/000057150. PubMed.
7 Lenk R, Likar R. Cannabinoids in medicine. Wien Med Wochenschr.
2008;(23-24):668–73. http://dx.doi.org/10.1007/s10354-008-0619-7.
PubMed.
8 Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacolog-
ic and clinical effects of medical cannabis. Pharmacotherapy.
2013;(2):195–209. http://dx.doi.org/10.1002/phar.1187. PubMed.
9 Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerg-
ing target of pharmacotherapy. Pharmacol Rev. 2006;(3):389–462.
http://dx.doi.org/10.1124/pr.58.3.2. PubMed.
10 Vemuri VK, Makriyannis A. Medicinal chemistry of cannabinoids. Clin
Pharmacol Ther. 2015;(6):553–8. http://dx.doi.org/10.1002/cpt.115.
PubMed.
11 Göbel H. Dronabinol-Therapie: Cannabis in der Medizin, chronische
Schmerzen, Schmerztherapie nach Querschnittslähmung, diabetische
Polyneuropathie, neuropsychiatrische Erkrankungen, Langzeittherapie
bei Multipler Sklerose, Anorexie-Kachexie-Syndrom, rechtliche Aspek-
te. Springer; 2004.
12 Noyes R, Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties
of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther.
1975;(1):84–9. http://dx.doi.org/10.1002/cpt197518184. PubMed.
13 Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. A multicenter
dose-escalation study of the analgesic and adverse effects of an oral
cannabis extract (Cannador) for postoperative pain management. Anes-
thesiology. 2006;(5):1040–6. http://dx.doi.org/10.1097/
00000542-200605000-00021. PubMed.
14 Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids.
J Opioid Manag. 2009;(6):341–57. PubMed.
15 Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R,
Fallon MT. Multicenter, double-blind, randomized, placebo-controlled,
parallel-group study of the efficacy, safety, and tolerability of THC:CBD
extract and THC extract in patients with intractable cancer-related pain.
J Pain Symptom Manage. 2010;(2):167–79. http://dx.doi.org/10.1016/
j.jpainsymman.2009.06.008. PubMed.
16 Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L,
Weinstein S, et al. Nabiximols for opioid-treated cancer patients with
poorly-controlled chronic pain: a randomized, placebo-controlled, grad-
ed-dose trial. J Pain. 2012;(5):438–49. http://dx.doi.org/10.1016/
j.jpain.2012.01.003. PubMed.
17 Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al.
Smoked cannabis for chronic neuropathic pain: a randomized controlled
trial. CMAJ. 2010;(14):E694–701. http://dx.doi.org/10.1503/
cmaj.091414. PubMed.
18 Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines
D. Sativex successfully treats neuropathic pain characterised by allody-
nia: a randomised, double-blind, placebo-controlled clinical trial. Pain.
2007;(1-3):210–20. http://dx.doi.org/10.1016/j.pain.2007.08.028.
PubMed.
19 United Nations Office on Drug and Crime (UNODC). Schedules of the
Convention on Psychotropic Substances of 1971. In: The International
Drug Control Conventions. New York: United Nations; 2013 pp 67–106.
20 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez
AV, et al. Cannabinoids for Medical Use: A Systematic Review and
Meta-analysis. JAMA. 2015;(24):2456–73. http://dx.doi.org/10.1001/ja-
ma.2015.6358. PubMed.
21 Fankhauser M. Station Dispensary in Langnau Emmental - Curaplant.
2016.
22 EpiData Association. EpiData Software. EpiData Software. 2001.
23 Federal Statistical Office (FSO). Classification of 7 territorial units of
Switzerland (7 major regions)- Basic Statistics. Swiss Statistics. 2013.
24 World Health Organization. WHO | International Classification of Dis-
eases (ICD). Geneva: WHO; 2016.
25 Schweizerisches Institut für ärztliche Weiter- und Fortbildung [Swiss In-
stitute of Advanced Medical Education]. Facharzttitel und Schwerpunk-
te (Weiterbildung) [Specialization title and main emphasis in advanced
medical education]. 2016. Available from: http://www.fmh.ch/bildung-
siwf/fachgebiete/facharzttitel-und-schwerpunkte.html
26 European Commission [internet]. Eurostat / Regional Statistics Illustrat-
ed. Eurostat Your key to European statistics. 2013. Available from:
http://ec.europa.eu/eurostat/cache/RCI/#?vis=nuts2.labourmar-
ket&lang=en
27 Madras B. Update of cannabis and its medical use. Geneva: World
Health Organization; 2015.
28 Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F.
The medicinal use of cannabis and cannabinoids--an international cross-
sectional survey on administration forms. J Psychoactive Drugs.
2013;(3):199–210. http://dx.doi.org/10.1080/02791072.2013.805976.
PubMed.
29 Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use
in California, 2012. Drug Alcohol Rev. 2015;(2):141–6.
http://dx.doi.org/10.1111/dar.12207. PubMed.
30 Swift W, Gates P, Dillon P. Survey of Australians using cannabis for
medical purposes. Harm Reduct J. 2005;(1):18. http://dx.doi.org/
10.1186/1477-7517-2-18. PubMed.
31 Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al.
Cannabis for therapeutic purposes: patient characteristics, access, and
Original article Swiss Med Wkly. 2017;147:w14463
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 11
reasons for use. Int J Drug Policy. 2013;(6):511–6. http://dx.doi.org/
10.1016/j.drugpo.2013.08.010. PubMed.
32 Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the
UK: results of a nationwide survey. Int J Clin Pract. 2005;(3):291–5.
http://dx.doi.org/10.1111/j.1742-1241.2004.00271.x. PubMed.
33 Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated
With Decreased Opiate Medication Use in a Retrospective Cross-Sec-
tional Survey of Patients With Chronic Pain. J Pain. 2016;(6):739–44.
http://dx.doi.org/10.1016/j.jpain.2016.03.002. PubMed.
34 Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescrip-
tion Medication Use In Medicare Part D. Health Aff (Millwood).
2016;(7):1230–6. http://dx.doi.org/10.1377/hlthaff.2015.1661. PubMed.
35 St-Amant H, Ware MA, Julien N, Lacasse A. Prevalence and determi-
nants of cannabinoid prescription for the management of chronic non-
cancer pain: a postal survey of physicians in the Abitibi-Témiscamingue
region of Quebec. CMAJ Open. 2015;(2):E251–7. http://dx.doi.org/
10.9778/cmajo.20140095. PubMed.
36 Belyea DA, Alhabshan R, Del Rio-Gonzalez AM, Chadha N, Lamba T,
Golshani C, et al. Marijuana Use Among Patients With Glaucoma in a
City With Legalized Medical Marijuana Use. JAMA Ophthalmol.
2016;(3):259–64. http://dx.doi.org/10.1001/jamaophthalmol.2015.5209.
PubMed.
37 Swiss Drug Compendium. Product information for Sativex. Available
from: http://compendium.ch/mpro/mnr/24719/html/de. 2016.
38 The Lancet Oncology. Cannabis: high time for evidence-based policies.
Lancet Oncol. 2017;(1):1. http://dx.doi.org/10.1016/
S1470-2045(16)30642-8. PubMed.
Original article Swiss Med Wkly. 2017;147:w14463
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 7 of 11
Appendix Supplementary tables and figures
Table S1: Characteristics of patients granted exceptional licences for therapeutic use of cannabinoids, by main symptoms pain and spasticity.
Variablen (%) Pain*n = 632 Spasticityn = 476
Age (years)
10–19 3 (0.5) 10 (2.1)
20–39 53 (8.4) 64 (13.5)
40–64 333 (52.7) 298 (62.6)
65–79 183 (29.0) 92 (19.3)
80–99 60 (9.5) 12 (2.5)
Mean (standard deviation), years 60 (15.0) 53 (14.5)
Sex
Male 248 (39.2) 219 (46.0)
Female 384 (60.8) 257 (54.0)
Diagnosis group (ICD-10 codes)
Diseases of the nervous system (G00–G99) 140 (22.2) 427 (89.7)
Diseases of the musculoskeletal system (M00–M99) 297 (47.0) 3 (0.6)
Cancer (C00–C97) 75 (11.9) 0
Injury, poisoning, and other conditions with external causes (S00–T98) 42 (6.7) 4 (0.8)
Diseases of the circulatory system (I00–I99) 8 (1.3) 15 (3.2)
Infectious and parasitic diseases (A00–B99) 14 (2.2) 3 (0.6)
Mental and behavioural disorders (F00–F99) 4 (0.6) 11 (2.3)
Diseases of the digestive system (K00–K93) 3 (0.5) 0
Diseases of the respiratory system (J00–J99) 1 (0.2) 0
Unclear 48 (7.6) 13 (2.7)
Comedication†
None 384 (60.8) 287 (60.3)
At least one drug 248 (39.2) 189 (39.7)
Analgesics 206 (83.1) 23 (12.2)
Muscle relaxant 22 (8.9) 142 (75.1)
Anticonvulsant 77 (31.1) 39 (20.6)
Immunosuppressive 7 (2.8) 18 (9.5)
Cytotoxic agents 12 (4.8) 4 (2.1)
Antidepressants 21 (8.5) 9 (4.8)
Parkinson medication 1 (0.4) 4 (2.1)
Others 3 (1.2) 13 (6.9)
Reimbursement
None (out of pocket) 588 (93.0) 415 (87.2)
Health insurance 37 (5.9) 56 (11.8)
Disability / accident insurance 7 (1.1) 5 (1.1)
* Pain includes neuropathic pain † It is possible that some patients have more than one treatment
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Table S2: Complete list of diagnoses in patients granted exceptional licenses for therapeutic use of cannabinoids.
Diagnosis (ICD-10 codes) Number (%)
Diseases of the nervous system (G00–G99) 580 (48.6)
Multiple sclerosis 257 (21.5)
Spinal muscular atrophy and related syndromes 65 (5.5)
Paraplegia and tetraplegia 62 (5.2)
Hereditary and idiopathic neuropathy 30 (2.5)
Parkinson disease 17 (1.4)
Nerve root and plexus disorders 15 (1.3)
Migraine 13 (1.0)
Cerebral palsy 11 (0.9)
Other disorder of central nervous systems 10 (0.8)
Hemiplegia 10 (0.8)
Other extrapyramidal and movement disorders 9 (0.8)
Epilepsy 8 (0.7)
Other polyneuropathies 8 (0.7)
Other paralytic syndromes 8 (0.7)
Huntington disease 6 (0.5)
Other headache syndromes 6 (0.5)
Disorders of trigeminal nerve 6 (0.5)
Other diseases of spinal cord 6 (0.5)
Other degenerative disease of nervous system 5 (0.4)
Other disorders of peripheral nervous system 5 (0.4)
Dystonia 5 (0.4)
Encephalitis, myelitis and encephalomyelitis 4 (0.3)
Postpolio syndrome 3 (0.3)
Inflammatory polyneuropathy 3 (0.3)
Polyneuropathy in diseases classified elsewhere 3 (0.3)
Other demyelinating diseases of central nervous system 2 (0.2)
Other neurological diseases 3 (0.3)
Diseases of the musculoskeletal system (M00–M99) 300 (25.2)
Soft tissue disorders, not elsewhere classified 119 (10.0)
Dorsalgia 97 (8.1)
Polyarthrosis 19 (1.6)
Other systematic involvement of connective tissue 13 (1.1)
Other arthritis 12 (1.0)
Other rheumatoid arthritis 11 (0.9)
Other joint disorders, not elsewhere classified 10 (0.8)
Seropositive rheumatoid arthritis 8 (0.7)
Gonarthrosis 4 (0.3)
Scoliosis 2 (0.2)
Other diseases of the musculoskeletal system 5 (0.4)
Cancer (C00–C97) 121 (10.1)
Breast 29 (2.4)
Lung 18 (1.5)
Colon 12 (1.0)
Pharynx and oesophagus 8 (0.7)
Pancreas 8 (0.7)
Stomach 6 (0.5)
Prostate 6 (0.5)
Hodgkin lymphoma 5 (0.4)
Kidney 4 (0.3)
Brain 4 (0.3)
Follicular lymphoma 3 (0.3)
Cervix uteri 3 (0.3)
Lymphoid leukaemia 3 (0.3)
Rectum 2 (0.2)
Uterus 2 (0.2)
Ovary 2 (0.2)
Bladder 2 (0.2)
Multiple myeloma 2 (0.2)
Anus 1 (0.1)
Injury, poisoning, and other conditions with external causes (S00–T98) 48 (4.0)
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Diagnosis (ICD-10 codes) Number (%)
Complications of surgical and medical care, not elsewhere classified 48 (4.0)
Diseases of the circulatory system (I00–I99) 23 (1.9)
Cerebral infarction 9 (0.8)
Sequelae of cerebrovascular disease 5 (0.4)
Aortic aneurysm and dissection 3 (0.3)
Other nontraumatic intracranial haemorrhage 2 (0.2)
Intracerebral haemorrhage 2 (0.2)
Other cerebrovascular diseases 2 (0.2)
Infectious and parasitic diseases (A00–B99) 22 (1.8)
Zoster (Herpes zoster) 9 (0.8)
HIV diseases resulting in infectious and parasitic disease 7 (0.6)
Other bacterial diseases, not elsewhere described 6 (0.5)
Mental and behavioural disorders (F00–F99) 17 (1.4)
Tic disorder 11 (0.9)
Somatoform disorders 5 (0.4)
Recurrent depressive disorder 1 (0.1)
Diseases of the digestive system (K00–K93) 6 (0.5)
Ulcerative colitis 2 (0.2)
Irritable bowel syndrome 2 (0.2)
Others diseases of digestive system 2 (0.2)
Diseases of the respiratory system (J00–J99) 1 (0.1)
Emphysema 1 (0.1)
Unclear 75 (6.3)
Figure S1: Nomenclature of Territorial Units for Statistics (NUTS) regions of Switzerland.From: Tschubby - Eigenes Werk, CC BY-SA 3.0,
https://commons.wikimedia.org/w/index.php?curid=45742802
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Figure S2: Number of patients with treatment of cannabinoids per 100 000 residents by region and calendar year. Numbers on the bars indi-
cate the rate in that region.
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